Author/Authors :
Yuan، نويسنده , , Qianying and Cai، نويسنده , , Shaoxin and Zhang، نويسنده , , Xuenong and Liu، نويسنده , , Ziwei and Li، نويسنده , , Zhaoming and Luo، نويسنده , , Xuelai and Xiong، نويسنده , , Chaomei and Wang، نويسنده , , Jianping and Hu، نويسنده , , Junbo and Ruan، نويسنده , , Jinlan، نويسنده ,
Abstract :
RY10-4, a novel protoapigenone analog, shows potent cytotoxicity against a broad spectrum of human cancer cells. Here we investigate its anti-tumor activity on breast cancer. The results indicated that RY10-4 suppressed proliferation, arrested cell cycle, induced apoptosis and inhibited invasion in MDA-MB-231, MCF-7 and SKBR3 breast cancer cells. Western blot analysis showed that RY10-4 down-regulated the PI3K/Akt signaling pathway and inhibited doxorubicin-induced p-Akt. Moreover, it effectively suppressed tumor growth in mice without major side effects. Therefore, RY10-4 had potential anti-tumor activity, and could be used as a lead to design more potent derivatives.
Keywords :
RY10-4 , Anti-tumor , breast cancer , PI3K/AKT
